Early-Pregnancy Maternal BMI and Offspring MS Risk Rise in Step With Adiposity
Maternal body mass index in early pregnancy was associated with a higher risk of multiple sclerosis in offspring in one of the largest population-based studies to examine the question. The cohort drew on Swedish national health and demographic registers and followed 1,524,863 singleton children born between 1992 and 2007 through 2025, giving the analysis unusual breadth and long follow-up for a prenatal exposure that is often difficult to measure with precision.
The signal was not subtle. Children of women with overweight and obesity in early pregnancy experienced higher hazards of later MS than children born to women with normal-weight BMI. The adjusted hazard ratio was 1.20 for maternal overweight and 1.35 for maternal obesity, using normal weight as the reference. In a field where many prenatal associations are diluted by later life exposures, these estimates were notable for persisting across a registry-based design that captured BMI at the first antenatal visit rather than relying on retrospective recall.
One sentence captures the clinical weight of the finding: the maternal metabolic milieu in early gestation may be relevant to neuroimmune risk decades later.
A Rare Long View of Prenatal Risk
MS emerged in 1,539 offspring, representing 0.1% of the cohort, at a median age of 24 years, with an interquartile range of 20 to 27 years. Incidence rates by maternal BMI category were 0.37 per 10,000 person-years for both underweight and normal-weight mothers, 0.42 for overweight, and 0.45 for obesity. Those absolute differences were modest, but they moved in a consistent direction and tracked with the adjusted time-to-event analyses.
The study design matters because it reduces several classic weaknesses of pregnancy epidemiology. BMI was prospectively recorded in routine antenatal care, not reconstructed from memory after the child’s diagnosis. MS outcome ascertainment required at least three ICD-10 G35 codes on separate dates, a stricter definition that reduces the chance of misclassifying transient or uncertain neurologic evaluations as disease. The result is a cleaner longitudinal picture of risk accumulation across childhood and early adulthood.
Why Maternal Adiposity Could Influence Neuroimmune Susceptibility
The biological explanation remains inferential, but the pathway is plausible. Maternal obesity is associated with chronic low-grade inflammation, altered lipid metabolism, insulin resistance, and changes in placental signaling. During early gestation, when fetal immune programming and neurodevelopment are still taking shape, that environment may affect tolerance, inflammatory set points, and later susceptibility to autoimmune disease. MS is not a disease that begins at diagnosis; it develops after years of interaction between inherited risk and environmental exposures, and prenatal metabolic conditions could plausibly be part of that early architecture.
The onset-specific analyses fit that framework. Adult-onset MS showed similar findings, while paediatric-onset estimates were less precise but still directionally consistent. Each 1-unit increase in maternal BMI was associated with a 3% higher hazard of overall offspring MS, a 4% higher hazard of paediatric-onset disease, and a 3% higher hazard of adult-onset disease. The dose-response pattern strengthens the argument that the association is not simply a threshold effect driven only by the most extreme BMI categories.
The Association Persisted Beyond Pregnancy Complications
The excess risk did not disappear after pregnancies with major complications were excluded. That is important because adverse pregnancy outcomes can act as confounders, intermediates, or markers of broader maternal illness, and it would have been easy for the association to evaporate once those pregnancies were removed. Instead, the relationship held, suggesting that the link is not fully explained by complications such as those that complicate gestation or delivery.
This leaves clinicians with a familiar but important epidemiologic message: maternal BMI in early pregnancy may be a marker of fetal immune programming rather than merely a proxy for pregnancy adversity. It does not mean that maternal adiposity causes MS in a direct or deterministic way. It does mean that the prenatal window deserves more attention in MS etiology than it has received in large-scale studies to date.
What the Numbers Can and Cannot Say at the Bedside
No prenatal exposure should be translated into individual prediction without caution. The absolute event rate remained low, and most children born to women with obesity did not develop MS. The study also cannot establish causality, and registry data cannot capture every relevant lifestyle, nutritional, genetic, or environmental factor that might influence both maternal BMI and offspring autoimmune risk.
Still, the public health relevance is difficult to ignore. MS typically appears years after the fetal period, so any maternal exposure that leaves a durable imprint on immune development deserves scrutiny. This analysis adds prospective, nationwide evidence that maternal adiposity in early pregnancy belongs in that discussion. It also raises a more precise research question for future work: whether the prenatal metabolic environment can be modified in ways that change long-term neuroimmune risk, or whether maternal BMI functions mainly as a marker for more complex biological and social processes that begin before birth.
Registry Strengths, but No Final Answer
The study drew strength from Sweden’s national registers, long follow-up, and a large denominator that allowed the authors to examine both childhood-onset and adult-onset MS. Ethical approval was secured from the Swedish Ethical Review Authority, and informed consent was waived because the study used anonymized registry data. Data availability remained restricted by privacy and data protection regulations.
Even with those strengths, the findings remain preprint data and have not yet undergone peer review. Replication in other populations, with different distributions of maternal BMI, obstetric care, and MS incidence, will be essential before the association can be treated as settled. For now, the study offers the clearest large-scale indication yet that early-pregnancy maternal BMI may be linked to later offspring MS risk, with a risk gradient that is consistent, biologically plausible, and still open to refinement through further epidemiologic and mechanistic work.